Protagonist Therapeutics, Inc. (PTGX)
NASDAQHealth CareBiotechnologySnapshot 2026-10-30
$144.85+0.35%
Close 2026-10-30 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-30
Research Workspace
Put PTGX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisManagement screens strong on capital allocation, market reaction to earnings.
View ManagementExpectations look high — what the market is pricing in runs ahead of what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskPTGX's bet rests on strong recent performance, though its revenue growth may be slowing. Revenue grew 99% year over year in Q1 FY2026, and Q2 FY2026 earnings beat consensus. PTGX trades at 37× sales versus a 9× peer median, near its 37× historical multiple. The market is pricing in more growth than our forecast, leaving expectations full. Our model puts the next-quarter miss probability near 40%. Fragile earnings quality means reported profits are not well backed by cash. Peer multiples imply a price about 38% below where it trades. Our read remains intact; this read is provisional.
Trailing returns as of 2026-10-30. PTGX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 14 analysts currently covering PTGX (as of Oct 2026).
Based on 8 Wall Street analysts offering 12-month price targets for PTGX in the last 4 months.
Continue this research
Compare PTGX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| PTGX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 5 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put PTGX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance clinical pipeline with key peptide programs
Profit indicates progress in clinical pipeline and potential blockbuster drugs.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $144.85
The last 12 months of price, then the range of analyst 12-month targets from today’s $144.85.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Generate royalties and milestone revenue from collaborations
Approval triggers significant royalty and milestone revenue.
Advances: Achieve regulatory and commercial milestones for partnered assets
FDA approval supports regulatory milestones for partnered assets.
Advances: Achieve regulatory and commercial milestones for partnered assets
FDA approval supports regulatory milestones for partnered assets.
CEO stock sale raises concerns about leadership commitment.
Advances: Advance clinical pipeline with key peptide programs
FDA approval supports advancement of clinical pipeline.
